Literature DB >> 25862913

High expression of phospho-H2AX predicts a poor prognosis in colorectal cancer.

Yi-Chen Lee1, Tzu Chieh Yin2, Yi-Ting Chen3, Chee-Yin Chai4, Jaw Yuan Wang2, Mei-Chi Liu5, Yuan-Chien Lin6, Jung Yu Kan7.   

Abstract

BACKGROUND/AIM: Colorectal cancer (CRC) is one of the most common causes of cancer-related deaths worldwide. DNA double-strand breaks (DSBs) are deleterious lesions that can lead to chromosomal anomalies, genomic instability and cancer. The histone H2AX plays an important role in response to DNA damage and phosphorylation of H2AX (p-H2AX) is evidence of DSBs. The aim of this study was to evaluate the clinical significance of p-H2AX expression in CRC. PATIENTS AND METHODS: p-H2AX expression in CRC tissues was analyzed by immunohistochemistry and correlated with clinicopathological variables using the chi-square test. The prognostic value of p-H2AX for distant metastasis-free survival (DMFS) and overall survival (OS) was evaluated by Kaplan-Meier estimates and the individual prognostic components were analyzed with Cox regression analysis.
RESULTS: A high p-H2AX expression in CRC tissues was associated with tumor stage and perineurial invasion. Furthermore, a high p-H2AX expression was associated with poor DMFS and OS. Cox regression analysis also revealed that p-H2AX was an independent predictor of DMFS and OS.
CONCLUSION: A high p-H2AX expression in CRC tissues is associated with a more malignant cancer behavior, as well as poor patient survival. p-H2AX may, therefore, be an independent prognostic predictor for CRC, as well as a potential therapeutic target. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  colorectal cancer; immunohisto che mistry; phospho-H2AX; prognosis

Mesh:

Substances:

Year:  2015        PMID: 25862913

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

Review 1.  Global histone post-translational modifications and cancer: Biomarkers for diagnosis, prognosis and treatment?

Authors:  Shafqat Ali Khan; Divya Reddy; Sanjay Gupta
Journal:  World J Biol Chem       Date:  2015-11-26

2.  Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancer.

Authors:  Yuchen Guo; Monica Gabola; Rossano Lattanzio; Conception Paul; Valérie Pinet; Ruizhi Tang; Hulya Turali; Julie Bremond; Ciro Longobardi; Chloé Maurizy; Quentin Da Costa; Pascal Finetti; Florence Boissière-Michot; Benjamin Rivière; Céline Lemmers; Séverine Garnier; François Bertucci; Inti Zlobec; Karim Chebli; Jamal Tazi; Rania Azar; Jean-Marie Blanchard; Peter Sicinski; Emilie Mamessier; Bénédicte Lemmers; Michael Hahne
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

3.  Anacardic acid sensitizes prostate cancer cells to radiation therapy by regulating H2AX expression.

Authors:  Kun Yao; Xianzhen Jiang; Leye He; Yuxin Tang; Guangming Yin; Qing Zeng; Zhiqiang Jiang; Jing Tan
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

4.  ATAD2 Overexpression Identifies Colorectal Cancer Patients with Poor Prognosis and Drives Proliferation of Cancer Cells.

Authors:  Yang Luo; Guang-Yao Ye; Shao-Lan Qin; Min-Hao Yu; Yi-Fei Mu; Ming Zhong
Journal:  Gastroenterol Res Pract       Date:  2015-11-30       Impact factor: 2.260

Review 5.  Circulating Nucleosomes and Nucleosome Modifications as Biomarkers in Cancer.

Authors:  Peter McAnena; James A L Brown; Michael J Kerin
Journal:  Cancers (Basel)       Date:  2017-01-08       Impact factor: 6.639

6.  Schistosoma mansoni eggs induce Wnt/β-catenin signaling and activate the protooncogene c-Jun in human and hamster colon.

Authors:  Jakob Weglage; Friederike Wolters; Laura Hehr; Jakob Lichtenberger; Celina Wulz; Felix Hempel; Anne Baier; Thomas Quack; Kernt Köhler; Thomas Longerich; Gabriele Schramm; Karuna Irungbam; Heike Mueller; Verena von Buelow; Annette Tschuschner; Margarete Odenthal; Uta Drebber; Maha El Arousy; Leandra N Z Ramalho; Katrin Bankov; Peter Wild; Jörn Pons-Kühnemann; Jonas Tschammer; Christoph G Grevelding; Elke Roeb; Martin Roderfeld
Journal:  Sci Rep       Date:  2020-12-23       Impact factor: 4.379

Review 7.  Use of Personalized Biomarkers in Metastatic Colorectal Cancer and the Impact of AI.

Authors:  Simona-Ruxandra Volovat; Iolanda Augustin; Daniela Zob; Diana Boboc; Florin Amurariti; Constantin Volovat; Cipriana Stefanescu; Cati Raluca Stolniceanu; Manuela Ciocoiu; Eduard Alexandru Dumitras; Mihai Danciu; Delia Gabriela Ciobanu Apostol; Vasile Drug; Sinziana Al Shurbaji; Lucia-Georgiana Coca; Florin Leon; Adrian Iftene; Paul-Corneliu Herghelegiu
Journal:  Cancers (Basel)       Date:  2022-10-03       Impact factor: 6.575

Review 8.  Histone Modifications and their Role in Colorectal Cancer (Review).

Authors:  Jingchun Qin; Bin Wen; Yuqi Liang; Weitao Yu; Huixuan Li
Journal:  Pathol Oncol Res       Date:  2019-05-04       Impact factor: 3.201

9.  Impact of DNA double-strand breaks on pancreaticobiliary maljunction carcinogenesis.

Authors:  Yasuhiro Kuraishi; Takeshi Uehara; Takashi Muraki; Mai Iwaya; Yasuhiro Kinugawa; Tomoyuki Nakajima; Takayuki Watanabe; Yusuke Miyagawa; Takeji Umemura
Journal:  Diagn Pathol       Date:  2021-08-09       Impact factor: 2.644

10.  VprBP directs epigenetic gene silencing through histone H2A phosphorylation in colon cancer.

Authors:  Nikhil Baban Ghate; Sangnam Kim; Erin Spiller; Sungmin Kim; Yonghwan Shin; Suhn K Rhie; Goar Smbatyan; Heinz-Josef Lenz; Shannon M Mumenthaler; Woojin An
Journal:  Mol Oncol       Date:  2021-08-08       Impact factor: 6.603

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.